Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Congenital Heart Disease Clear all
Completed Not applicable Interventional

Marfan Syndrome Moderate Exercise Pilot

NCT04641325
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Exercise Intervention Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

NCT03153137
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Macitentan 10 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
12 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 11, 2026, 4:01 AM EDT
Completed No phase listed Observational

Myocardial Perfusion and Scarring in Adults With Congenital Heart Disease

NCT02861365
View directory record Official record
Conditions
Cardiac Disease
Interventions
Not listed
Lead sponsor
Children's National Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome

NCT00723801
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Atenolol, Losartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oxygen Uptake Kinetics During Submaximal Exercise in Adults With Down Syndrome

NCT05995223
View directory record Official record
Conditions
Down Syndrome
Interventions
Submaximal exercise protocol
Other
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 35 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 11, 2026, 4:01 AM EDT
Recruiting Not applicable Interventional

Marfan Syndrome Moderate Exercise Trial II

NCT05809323
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Exercise Intervention Group, Control Group
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 11, 2026, 4:01 AM EDT
Terminated No phase listed Observational

Myocardial Perfusion and Scarring in Congenital Heart Disease

NCT01639937
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease

NCT00864851
View directory record Official record
Conditions
Fabry Disease
Interventions
Replagal
Biological
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Tucson, Arizona • Iowa City, Iowa • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

NCT02412098
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Eleclazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

NCT01560260
View directory record Official record
Conditions
Carney Complex, Chondrosarcoma, Gastrointestinal Stromal Tumor, Paraganglioma
Interventions
Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Palo Alto, California • Iowa City, Iowa • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 11, 2026, 4:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

NCT00861848
View directory record Official record
Conditions
Kawasaki Disease, Heart Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
12 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 11, 2026, 4:01 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies

NCT04888936
View directory record Official record
Conditions
Costello Syndrome, Noonan Syndrome, Cardiofaciocutaneous Syndrome, Legius Syndrome, Capillary Arteriovenous Malformation Syndrome, RASopathy
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 99 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2035
U.S. locations
2
States / cities
Bethesda, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 11, 2026, 4:01 AM EDT
Recruiting Not applicable Interventional

Implementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework

NCT07559253
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Accessible Care Model Visit, Recruitment Interviews, Participating Patient-Support Person Interviews, Participating Patient-Support Person Surveys, Participating Provider Interviews and surveys, Unstructured and semi-structured interviews
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years to 26 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 11, 2026, 4:01 AM EDT
Terminated Phase 1 Interventional

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

NCT03114319
View directory record Official record
Conditions
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
Interventions
TNO155, TNO155 in combination with EGF816 (nazartinib)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 11, 2026, 4:01 AM EDT
Completed No phase listed Observational

Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome

NCT01705925
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
Up to 20 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 11, 2026, 4:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Relationship Between Brain MRI Phenotypes, Genes and Cognitive Outcome in CHD Adults

NCT05258981
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
MRI
Diagnostic Test
Lead sponsor
Boston Children's Hospital
Other
Eligibility
24 Years to 35 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 11, 2026, 4:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

NCT06381466
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
AZD0233, AZD0233 Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Spironolactone in Adult Congenital Heart Disease

NCT01069510
View directory record Official record
Conditions
Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
Interventions
Spironolactone 25mg, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 11, 2026, 4:01 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

NCT06464588
View directory record Official record
Conditions
Dilated Cardiomyopathy
Interventions
Allogeneic Neonatal mesenchymal stromal cells (nMSCs)
Biological
Lead sponsor
Emory University
Other
Eligibility
4 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 11, 2026, 4:01 AM EDT
Terminated No phase listed Observational

Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique

NCT00384163
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

NCT04252339
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult
Interventions
RLY-1971
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 11, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 11, 2026, 4:01 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

NCT01980979
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Remodulin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 11, 2026, 4:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 11, 2026, 4:01 AM EDT